Influenza Medication Market Size by The Government In Developed, Region – Segment-Level Market Assessment, Growth Opportunity Analysis, Competitive Mapping & Forecast to 2029

6.8%
CAGR (2021-2029)
113 USD Mn.
Market Size
307
Report Pages
130
Market Tables

Overview

Influenza Medication Market is expected to grow at a CAGR of 6.8% during the forecast period. Influenza Medication Market is expected to reach US$ 1133.43 Mn. by 2029.

Influenza Medication MarketTo know about the Research Methodology :- Request Free Sample Report

Influenza Medication Market Dynamics:

Influenza medication contain antiviral drugs that are used in reaction to disease influenza. Influenza (flu), is a viral infection that attacks respiratory system like nose, throat and lungs. It is a viral infectious disease that includes three major types like A, B, and type C. The common symptoms of the disorder are cold, cough, fever, and sore throat, which can be severe or mild. The major classes of antiviral drugs used against influenza are neuraminidase inhibitors, such as zanamivir and oseltamivir, or inhibitors of the viral M2 protein, such as amantadine and rimantadine. These drugs can decrease the severity of symptoms and to reduce the risk of infection.The report study has analyzed revenue impact of COVID -19 pandemic on the sales revenue of market leaders, market followers and market disrupters in the report and same is reflected in our analysis.

The unmet medical needs within the annual influenza epidemics along with strong R&D focus resulting in new and advanced treatments and drugs, and increasing demand due to government stockpiling that are major driving factor of the market growth. For example, According to the CDC, nearby X% to xx% of the population is affected with the flu in the U.S. every year. Moreover, an expected xx people are hospitalized due to flu infection in the U.S. every year; of these xx% die due to flu complications. Favorable policies for treatment and prevention of influenza by the government in developed regions. These are the major drivers in the growth of influenza medication market. Patent expiry of key drugs and entry of generics and side effects of anti-influenza drug therapy are hamper the market growth globally.

Influenza Medication Market Segment Analysis:

Based on the distribution channels, the influenza medication market has been segmented into pharmacies, hospitals and clinics. The pharmacies segment held the largest share accounting around xx% share of global market in 2021 owing to increase in the number of pharmacy stores Patients discharged from hospitals or clinics with an influenza treatment plan to use influenza medication for a prescribed treatment duration prefer online or retail pharmacy purchase. The hospitals segment is hold the substantial market share of xx% in 2021. Hospitals normally preferred distribution channel segment, as the patients with HIV and cardiovascular disease related with Influenza. In hospitals, increasing incidence of influenza in-patients drives the growth of this segment.

Based on the product, the influenza medication market has been segmented into zanamivir, oseltamivir, peramivir, amantadine, rimantadine, and inosine. The oseltamivir segment held a significant share of XX% in the global market in 2018 owing to the rising use of oseltamivir in the treatment of flu triggered by H1N1 virus and prophylaxis.

Influenza Medication Market Regional Analysis:

Geographically, the influenza medication market has been segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America held the largest share of the Influenza medication market in 2018. The U.S. lead the Influenza medication market in North America owing to increasing acceptance of advanced and high-cost drug therapies, increased treatment rate, and favorable reimbursement policies in the country. The market in Asia Pacific is expected to expand at a high CAGR of xx% during the forecast period due to major contribution from developing countries, availability of low cost treatment and availability of better health care facilities. Increase in the number of public awareness programs for prevention and diagnosis of chronic diseases such as influenza has significantly reduced the incidence of influenza in Asia Pacific. China and India are highly populated countries with the maximum number of influenza patients making them major contributor to the growth of the market in Asia Pacific.

Influenza Medication Market Competitive landscape

Major Key players operating in this market are Daiichi Sankyo Company, GlaxoSmithKline plc, Natco Pharma, F. Hoffmann-La Roche Ltd., Teva Pharmaceutical Industries Ltd. Manufacturers in the Influenza Medication are focusing on competitive pricing as the strategy to capture significant market share. Moreover, strategic mergers and acquisitions and technological innovations are also the key focus areas of the manufacturers.

The objective of the report is to present comprehensive analysis of influenza medication market including all the stakeholders of the industry. The past and current status of the industry with forecasted market size and trends are presented in the report with the analysis of complicated data in simple language. The report covers the all the aspects of industry with dedicated study of key players that includes market leaders, followers and new entrants by region. PORTER, SVOR, PESTEL analysis with the potential impact of micro-economic factors by region on the market have been presented in the report. External as well as internal factors that are supposed to affect the business positively or negatively have been analyzed, which will give clear futuristic view of the industry to the decision makers.

The report also helps in understanding influenza medication market dynamics, structure by analyzing the market segments, and project the influenza medication market size. Clear representation of competitive analysis of key players by product type, price, financial position, product portfolio, growth strategies, and regional presence in the influenza medication market make the report investor’s guide.

Influenza Medication Market Scope: Inquire before buying

Influenza Medication Market, by Product type:

• Zanamivir
• Oseltamivir
• Peramivir
• Amantadine
• Rimantadine
• Inosine

Influenza Medication Market, by Distribution Channel:

• Hospitals
• Clinics
• Pharmacies

Influenza Medication Market, by Region:

• Asia Pacific
• North America
• Europe
• Latin America
• Middle East Africa

Influenza Medication Market Key Players:

• Daiichi Sankyo Company
• GlaxoSmithKline plc
• Natco Pharma
• F. Hoffmann-La Roche Ltd.
• Teva Pharmaceutical Industries Ltd.
• Sandoz International GmbH
• Sun Pharmaceutical Industries Ltd.
• Mylan, Inc.
• Emirates SkyCargo
• Sanofi
• Merck
• Pfizer
• Novarties
• Seqirus
• Genentech, Inc.
• Shionogi & Co., Ltd.
• BIOCRYST PHARMACEUTICALS, INC.
• Lupin Limited
• Amneal Pharmaceuticals LLC
• Macleods Pharmaceuticals Ltd.

Frequently Asked Questions:

1. Which region has the largest share in Influenza Medication Market?
Ans: North America region holds the highest share in 2021.

2. What is the growth rate of Influenza Medication Market?
Ans: The Influenza Medication Market is growing at a CAGR of 6.8% during forecasting period 2022-2029.

3. What is scope of the Influenza Medication market report?
Ans: Influenza Medication Market report helps with the PESTEL, PORTER, COVID-19 Impact analysis, Recommendations for Investors & Leaders, and market estimation of the forecast period.

4. Who are the key players in Influenza Medication market?
Ans: The important key players in the Influenza Medication Market are – Daiichi Sankyo Company, GlaxoSmithKline plc, Natco Pharma, F. Hoffmann-La Roche Ltd., Teva Pharmaceutical Industries Ltd., Sandoz International GmbH, Sun Pharmaceutical Industries Ltd., Mylan, Inc., Emirates SkyCargo, Sanofi, Merck, Pfizer, Novarties, Seqirus, Genentech, Inc., Shionogi & Co., Ltd., BIOCRYST PHARMACEUTICALS, INC., Lupin Limited, Amneal Pharmaceuticals LLC, and Macleods Pharmaceuticals Ltd.

5. What is the study period of this market?
Ans: The Influenza Medication Market is studied from 2021 to 2029.

Table of Contents

Influenza Medication Market 1. Preface 1.1. Report Scope and Market Segmentation 1.2. Research Highlights 1.3. Research Objectives 2. Assumptions and Research Methodology 2.1. Report Assumptions 2.2. Abbreviations 2.3. Research Methodology 2.3.1. Secondary Research 2.3.1.1. Secondary data 2.3.1.2. Secondary Sources 2.3.2. Primary Research 2.3.2.1. Data from Primary Sources 2.3.2.2. Breakdown of Primary Sources 3. Executive Summary: Global Influenza Medication Market Size, by Market Value (US$ Bn) 4. Market Overview 4.1. Introduction 4.2. Market Indicator 4.2.1. Drivers 4.2.2. Restraints 4.2.3. Opportunities 4.2.4. Challenges 4.3. Porter’s Analysis 4.4. Value Chain Analysis 4.5. Market Risk Analysis 4.6. SWOT Analysis 4.7. Industry Trends and Emerging Technologies 4.8. Patent Registration 5. Supply Side and Demand Side Indicators 6. Global Influenza Medication Market Analysis and Forecast 6.1. Global Influenza Medication Market Size & Y-o-Y Growth Analysis 6.1.1. North America 6.1.2. Europe 6.1.3. Asia Pacific 6.1.4. Middle East & Africa 6.1.5. South America 7. Global Influenza Medication Market Analysis and Forecast, by Product Type 7.1. Introduction and Definition 7.2. Key Findings 7.3. Global Influenza Medication Market Value Share Analysis, by Product Type 7.4. Global Influenza Medication Market Size (US$ Bn) Forecast, by Product Type 7.5. Global Influenza Medication Market Analysis, by Product Type 7.6. Global Influenza Medication Market Attractiveness Analysis, by Product Type 8. Global Influenza Medication Market Analysis and Forecast, by Distribution Channel 8.1. Introduction and Definition 8.2. Key Findings 8.3. Global Influenza Medication Market Value Share Analysis, by Distribution Channel 8.4. Global Influenza Medication Market Size (US$ Bn) Forecast, by Distribution Channel 8.5. Global Influenza Medication Market Analysis, by Distribution Channel 8.6. Global Influenza Medication Market Attractiveness Analysis, by Distribution Channel 9. Global Influenza Medication Market Analysis, by Region 9.1. Global Influenza Medication Market Value Share Analysis, by Region 9.2. Global Influenza Medication Market Size (US$ Bn) Forecast, by Region 9.3. Global Influenza Medication Market Attractiveness Analysis, by Region 10. North America Influenza Medication Market Analysis 10.1. Key Findings 10.2. North America Influenza Medication Market Overview 10.3. North America Influenza Medication Market Value Share Analysis, by Product Type 10.4. North America Influenza Medication Market Forecast, by Product Type 10.4.1. Zanamivir 10.4.2. Oseltamivir 10.4.3. Peramivir 10.4.4. Amantadine 10.4.5. Rimantadine 10.4.6. Inosine 10.5. North America Influenza Medication Market Value Share Analysis, by Distribution Channel 10.6. North America Influenza Medication Market Forecast, by Distribution Channel 10.6.1. Hospitals 10.6.2. Clinics 10.6.3. Pharmacies 10.7. North America Influenza Medication Market Value Share Analysis, by Country 10.8. North America Influenza Medication Market Forecast, by Country 10.8.1. U.S. 10.8.2. Canada 10.9. North America Influenza Medication Market Analysis, by Country 10.10. U.S. Influenza Medication Market Forecast, by Product Type 10.10.1. Zanamivir 10.10.2. Oseltamivir 10.10.3. Peramivir 10.10.4. Amantadine 10.10.5. Rimantadine 10.10.6. Inosine 10.11. U.S. Influenza Medication Market Forecast, by Distribution Channel 10.11.1. Hospitals 10.11.2. Clinics 10.11.3. Pharmacies 10.12. Canada Influenza Medication Market Forecast, by Product Type 10.12.1. Zanamivir 10.12.2. Oseltamivir 10.12.3. Peramivir 10.12.4. Amantadine 10.12.5. Rimantadine 10.12.6. Inosine 10.13. Canada Influenza Medication Market Forecast, by Distribution Channel 10.13.1. Hospitals 10.13.2. Clinics 10.13.3. Pharmacies 10.14. North America Influenza Medication Market Attractiveness Analysis 10.14.1. By Product Type 10.14.2. By Distribution Channel 10.15. PEST Analysis 10.16. Key Trends 10.17. Key Development 11. Europe Influenza Medication Market Analysis 11.1. Key Findings 11.2. Europe Influenza Medication Market Overview 11.3. Europe Influenza Medication Market Value Share Analysis, by Product Type 11.4. Europe Influenza Medication Market Forecast, by Product Type 11.4.1. Zanamivir 11.4.2. Oseltamivir 11.4.3. Peramivir 11.4.4. Amantadine 11.4.5. Rimantadine 11.4.6. Inosine 11.5. Europe Influenza Medication Market Value Share Analysis, by Distribution Channel 11.6. Europe Influenza Medication Market Forecast, by Distribution Channel 11.6.1. Hospitals 11.6.2. Clinics 11.6.3. Pharmacies 11.7. Europe Influenza Medication Market Value Share Analysis, by Country 11.8. Europe Influenza Medication Market Forecast, by Country 11.8.1. Germany 11.8.2. U.K. 11.8.3. France 11.8.4. Italy 11.8.5. Spain 11.8.6. Rest of Europe 11.9. Europe Influenza Medication Market Analysis, by Country 11.10. Germany Influenza Medication Market Forecast, by Product Type 11.10.1. Zanamivir 11.10.2. Oseltamivir 11.10.3. Peramivir 11.10.4. Amantadine 11.10.5. Rimantadine 11.10.6. Inosine 11.11. Germany Influenza Medication Market Forecast, by Distribution Channel 11.11.1. Hospitals 11.11.2. Clinics 11.11.3. Pharmacies 11.12. U.K. Influenza Medication Market Forecast, by Product Type 11.12.1. Zanamivir 11.12.2. Oseltamivir 11.12.3. Peramivir 11.12.4. Amantadine 11.12.5. Rimantadine 11.12.6. Inosine 11.13. U.K. Influenza Medication Market Forecast, by Distribution Channel 11.13.1. Hospitals 11.13.2. Clinics 11.13.3. Pharmacies 11.14. France Influenza Medication Market Forecast, by Product Type 11.14.1. Zanamivir 11.14.2. Oseltamivir 11.14.3. Peramivir 11.14.4. Amantadine 11.14.5. Rimantadine 11.14.6. Inosine 11.15. France Influenza Medication Market Forecast, by Distribution Channel 11.15.1. Hospitals 11.15.2. Clinics 11.15.3. Pharmacies 11.16. Italy Influenza Medication Market Forecast, by Product Type 11.16.1. Zanamivir 11.16.2. Oseltamivir 11.16.3. Peramivir 11.16.4. Amantadine 11.16.5. Rimantadine 11.16.6. Inosine 11.17. Italy Influenza Medication Market Forecast, by Distribution Channel 11.17.1. Hospitals 11.17.2. Clinics 11.17.3. Pharmacies 11.18. Spain Influenza Medication Market Forecast, by Product Type 11.18.1. Zanamivir 11.18.2. Oseltamivir 11.18.3. Peramivir 11.18.4. Amantadine 11.18.5. Rimantadine 11.18.6. Inosine 11.19. Spain Influenza Medication Market Forecast, by Distribution Channel 11.19.1. Hospitals 11.19.2. Clinics 11.19.3. Pharmacies 11.20. Rest of Europe Influenza Medication Market Forecast, by Product Type 11.20.1. Zanamivir 11.20.2. Oseltamivir 11.20.3. Peramivir 11.20.4. Amantadine 11.20.5. Rimantadine 11.20.6. Inosine 11.21. Rest of Europe Influenza Medication Market Forecast, by Distribution Channel 11.21.1. Hospitals 11.21.2. Clinics 11.21.3. Pharmacies 11.22. Europe Influenza Medication Market Attractiveness Analysis 11.22.1. By Product Type 11.22.2. By Distribution Channel 11.23. PEST Analysis 11.24. Key Trend 11.25. Key Development 12. Asia Pacific Influenza Medication Market Analysis 12.1. Key Findings 12.2. Asia Pacific Influenza Medication Market Overview 12.3. Asia Pacific Influenza Medication Market Value Share Analysis, by Product Type 12.4. Asia Pacific Influenza Medication Market Forecast, by Product Type 12.4.1. Zanamivir 12.4.2. Oseltamivir 12.4.3. Peramivir 12.4.4. Amantadine 12.4.5. Rimantadine 12.4.6. Inosine 12.5. Asia Pacific Influenza Medication Market Value Share Analysis, by Distribution Channel 12.6. Asia Pacific Influenza Medication Market Forecast, by Distribution Channel 12.6.1. Hospitals 12.6.2. Clinics 12.6.3. Pharmacies 12.7. Asia Pacific Influenza Medication Market Value Share Analysis, by Country 12.8. Asia Pacific Influenza Medication Market Forecast, by Country 12.8.1. China 12.8.2. India 12.8.3. Japan 12.8.4. ASEAN 12.8.5. Rest of Asia Pacific 12.9. Asia Pacific Influenza Medication Market Analysis, by Country 12.10. China Influenza Medication Market Forecast, by Product Type 12.10.1. Zanamivir 12.10.2. Oseltamivir 12.10.3. Peramivir 12.10.4. Amantadine 12.10.5. Rimantadine 12.10.6. Inosine 12.11. China Influenza Medication Market Forecast, by Distribution Channel 12.11.1. Hospitals 12.11.2. Clinics 12.11.3. Pharmacies 12.12. India Influenza Medication Market Forecast, by Product Type 12.12.1. Zanamivir 12.12.2. Oseltamivir 12.12.3. Peramivir 12.12.4. Amantadine 12.12.5. Rimantadine 12.12.6. Inosine 12.13. India Influenza Medication Market Forecast, by Distribution Channel 12.13.1. Hospitals 12.13.2. Clinics 12.13.3. Pharmacies 12.14. Japan Influenza Medication Market Forecast, by Product Type 12.14.1. Zanamivir 12.14.2. Oseltamivir 12.14.3. Peramivir 12.14.4. Amantadine 12.14.5. Rimantadine 12.14.6. Inosine 12.15. Japan Influenza Medication Market Forecast, by Distribution Channel 12.15.1. Hospitals 12.15.2. Clinics 12.15.3. Pharmacies 12.16. ASEAN Influenza Medication Market Forecast, by Product Type 12.16.1. Zanamivir 12.16.2. Oseltamivir 12.16.3. Peramivir 12.16.4. Amantadine 12.16.5. Rimantadine 12.16.6. Inosine 12.17. ASEAN Influenza Medication Market Forecast, by Distribution Channel 12.17.1. Hospitals 12.17.2. Clinics 12.17.3. Pharmacies 12.18. Rest of Asia Pacific Influenza Medication Market Forecast, by Product Type 12.18.1. Zanamivir 12.18.2. Oseltamivir 12.18.3. Peramivir 12.18.4. Amantadine 12.18.5. Rimantadine 12.18.6. Inosine 12.19. Rest of Asia Pacific Influenza Medication Market Forecast, by Distribution Channel 12.19.1. Hospitals 12.19.2. Clinics 12.19.3. Pharmacies 12.20. Asia Pacific Influenza Medication Market Attractiveness Analysis 12.20.1. By Product Type 12.20.2. By Distribution Channel 12.21. PEST Analysis 12.22. Key Trend 12.23. Key Development 13. Middle East & Africa Influenza Medication Market Analysis 13.1. Key Findings 13.2. Middle East & Africa Influenza Medication Market Overview 13.3. Middle East & Africa Influenza Medication Market Value Share Analysis, by Product Type 13.4. Middle East & Africa Influenza Medication Market Forecast, by Product Type 13.4.1. Zanamivir 13.4.2. Oseltamivir 13.4.3. Peramivir 13.4.4. Amantadine 13.4.5. Rimantadine 13.4.6. Inosine 13.5. Middle East & Africa Influenza Medication Market Value Share Analysis, by Distribution Channel 13.6. Middle East & Africa Influenza Medication Market Forecast, by Distribution Channel 13.6.1. Hospitals 13.6.2. Clinics 13.6.3. Pharmacies 13.7. Middle East & Africa Influenza Medication Market Value Share Analysis, by Country 13.8. Middle East & Africa Influenza Medication Market Forecast, by Country 13.8.1. GCC 13.8.2. South Africa 13.8.3. Rest of Middle East & Africa 13.9. Middle East & Africa Influenza Medication Market Analysis, by Country 13.10. GCC Influenza Medication Market Forecast, by Product Type 13.10.1. Zanamivir 13.10.2. Oseltamivir 13.10.3. Peramivir 13.10.4. Amantadine 13.10.5. Rimantadine 13.10.6. Inosine 13.11. GCC Influenza Medication Market Forecast, by Distribution Channel 13.11.1. Hospitals 13.11.2. Clinics 13.11.3. Pharmacies 13.12. South Africa Influenza Medication Market Forecast, by Product Type 13.12.1. Zanamivir 13.12.2. Oseltamivir 13.12.3. Peramivir 13.12.4. Amantadine 13.12.5. Rimantadine 13.12.6. Inosine 13.13. South Africa Influenza Medication Market Forecast, by Distribution Channel 13.13.1. Hospitals 13.13.2. Clinics 13.13.3. Pharmacies 13.14. Rest of Middle East & Africa Influenza Medication Market Forecast, by Product Type 13.14.1. Zanamivir 13.14.2. Oseltamivir 13.14.3. Peramivir 13.14.4. Amantadine 13.14.5. Rimantadine 13.14.6. Inosine 13.15. Rest of Middle East & Africa Influenza Medication Market Forecast, by Distribution Channel 13.15.1. Hospitals 13.15.2. Clinics 13.15.3. Pharmacies 13.16. Middle East & Africa Influenza Medication Market Attractiveness Analysis 13.16.1. By Product Type 13.16.2. By Distribution Channel 13.17. PEST Analysis 13.18. Key Trend 13.19. Key Development 14. South America Influenza Medication Market Analysis 14.1. Key Findings 14.2. South America Influenza Medication Market Overview 14.3. South America Influenza Medication Market Value Share Analysis, by Product Type 14.4. South America Influenza Medication Market Forecast, by Product Type 14.4.1. Zanamivir 14.4.2. Oseltamivir 14.4.3. Peramivir 14.4.4. Amantadine 14.4.5. Rimantadine 14.4.6. Inosine 14.5. South America Influenza Medication Market Value Share Analysis, by Distribution Channel 14.6. South America Influenza Medication Market Forecast, by Distribution Channel 14.6.1. Hospitals 14.6.2. Clinics 14.6.3. Pharmacies 14.7. South America Influenza Medication Market Value Share Analysis, by Country 14.8. South America Influenza Medication Market Forecast, by Country 14.8.1. Brazil 14.8.2. Mexico 14.8.3. Rest of South America 14.9. Brazil Influenza Medication Market Forecast, by Product Type 14.9.1. Zanamivir 14.9.2. Oseltamivir 14.9.3. Peramivir 14.9.4. Amantadine 14.9.5. Rimantadine 14.9.6. Inosine 14.10. Brazil Influenza Medication Market Forecast, by Distribution Channel 14.10.1. Hospitals 14.10.2. Clinics 14.10.3. Pharmacies 14.11. Mexico Influenza Medication Market Forecast, by Product Type 14.11.1. Zanamivir 14.11.2. Oseltamivir 14.11.3. Peramivir 14.11.4. Amantadine 14.11.5. Rimantadine 14.11.6. Inosine 14.12. Mexico Influenza Medication Market Forecast, by Distribution Channel 14.12.1. Hospitals 14.12.2. Clinics 14.12.3. Pharmacies 14.13. Rest of South America Influenza Medication Market Forecast, by Product Type 14.13.1. Zanamivir 14.13.2. Oseltamivir 14.13.3. Peramivir 14.13.4. Amantadine 14.13.5. Rimantadine 14.13.6. Inosine 14.14. Rest of South America Influenza Medication Market Forecast, by Distribution Channel 14.14.1. Hospitals 14.14.2. Clinics 14.14.3. Pharmacies 14.15. South America Influenza Medication Market Attractiveness Analysis 14.15.1. By Product Type 14.15.2. By Distribution Channel 14.16. PEST Analysis 14.17. Key Trend 14.18. Key Development 15. Company Profiles 15.1. Market Share Analysis, by Company 15.2. Competition Matrix 15.2.1. Competitive Benchmarking of key players by price, presence, market share, Applications and R&D investment 15.2.2. New Product Launches and Product Enhancements 15.2.3. Market Consolidation 15.2.3.1. M&A by Regions, Investment and Applications 15.2.3.2. M&A Key Players, Forward Integration and Backward Integration 15.3. Company Profiles: Key Players 15.3.1. Daiichi Sankyo Company 15.3.1.1. Company Overview 15.3.1.2. Financial Overview 15.3.1.3. Product Portfolio 15.3.1.4. Business Strategy 15.3.1.5. Recent Developments 15.3.1.6. Company Footprint 15.3.2. GlaxoSmithKline plc 15.3.3. Natco Pharma 15.3.4. F. Hoffmann-La Roche Ltd. 15.3.5. Teva Pharmaceutical Industries Ltd. 15.3.6. Sandoz International GmbH 15.3.7. Sun Pharmaceutical Industries Ltd. 15.3.8. Mylan, Inc. 15.3.9. Emirates SkyCargo 15.3.10. Sanofi 15.3.11. Merck 15.3.12. Pfizer 15.3.13. Novarties 15.3.14. Seqirus 15.3.15. Genentech, Inc. 15.3.16. Shionogi & Co., Ltd. 15.3.17. BIOCRYST PHARMACEUTICALS, INC. 15.3.18. Lupin Limited 15.3.19. Amneal Pharmaceuticals LLC 15.3.20. Macleods Pharmaceuticals Ltd. 16. Primary Key Insights